Interaksi Biktegravir, emtrisitabin, dan tenofovir alafenamid dan Buprenorfin dan nalokson

Biktegravir, emtrisitabin, dan tenofovir alafenamid dan Buprenorfin dan nalokson: kedua label peresepan menandai kombinasi ini dengan bahasa yang paling tegas, seperti kontraindikasi, peringatan kotak hitam, atau instruksi untuk menghindarinya.

Mayor

Jangan dikombinasikan tanpa arahan dokter yang meresepkan. Bahasa label di bawah ini adalah yang paling tegas yang digunakan FDA.

Apa kata label FDA

Dari label Biktegravir, emtrisitabin, dan tenofovir alafenamid (BIXLENVO) · berlaku sejak 2026-08-27

Mayor

Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

Narcotic analgesic for treatment of opioid dependence: buprenorphine, methadone buprenorphine: effects unknown methadone: effects unknown Initiation of buprenorphine or methadone in patients taking BIXLENVO: Carefully titrate the dose of buprenorphine or methadone to the desired effect; use the lowest feasible initial or maintenance dose.

Interaksi obatmenyebut Buprenorfin dan naloksonLihat label di DailyMed
Moderat

Initiation of BIXLENVO in patients taking buprenorphine or methadone: A dose adjustment for buprenorphine or methadone may be needed.

Interaksi obatmenyebut Buprenorfin dan naloksonLihat label di DailyMed
Moderat

Narcotic analgesics metabolized by CYP3A: e.g., fentanyl, oxycodone ↑ fentanyl ↑ oxycodone Careful monitoring of therapeutic effects and adverse reactions associated with CYP3A-metabolized narcotic analgesics (including potentially fatal respiratory depression) is recommended with co-administration.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Dari label Buprenorfin dan nalokson (Buprenorphine and Naloxone) · berlaku sejak 2026-06-16

Moderat

Antiretrovirals: Patients who are on chronic buprenorphine treatment should have their dose monitored if NNRTIs are added to their treatment regimen.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Minor

Examples: Rifampin, carbamazepine, phenytoin Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Minor

Examples: efavirenz, nevirapine, etravirine, delavirdine Antiretrovirals: Protease inhibitors (PIs) Clinical Impact: Studies have shown some antiretroviral protease inhibitors (PIs) with CYP3A4 inhibitory activity (nelfinavir, lopinavir/ritonavir, ritonavir) have little effect on buprenorphine pharmacokinetic and no significant pharmacodynamic effects.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Tanpa interaksi

Examples: atazanavir, ritonavir Antiretrovirals: Nucleoside reverse transcriptase inhibitors (NRTIs) Clinical Impact: Nucleoside reverse transcriptase inhibitors (NRTIs) do not appear to induce or inhibit the P450 enzyme pathway, thus no interactions with buprenorphine are expected.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.